Your browser doesn't support javascript.
loading
Myhre and LAPS syndromes: clinical and molecular review of 32 patients.
Michot, Caroline; Le Goff, Carine; Mahaut, Clémentine; Afenjar, Alexandra; Brooks, Alice S; Campeau, Philippe M; Destree, Anne; Di Rocco, Maja; Donnai, Dian; Hennekam, Raoul; Heron, Delphine; Jacquemont, Sébastien; Kannu, Peter; Lin, Angela E; Manouvrier-Hanu, Sylvie; Mansour, Sahar; Marlin, Sandrine; McGowan, Ruth; Murphy, Helen; Raas-Rothschild, Annick; Rio, Marlène; Simon, Marleen; Stolte-Dijkstra, Irene; Stone, James R; Sznajer, Yves; Tolmie, John; Touraine, Renaud; van den Ende, Jenneke; Van der Aa, Nathalie; van Essen, Ton; Verloes, Alain; Munnich, Arnold; Cormier-Daire, Valérie.
Afiliação
  • Michot C; INSERM U781 Unit, Department of Genetics, Institut Imagine, Paris Descartes University-Sorbonne Paris Cité, Necker Enfants-Malades Hospital, Paris, France.
  • Le Goff C; INSERM U781 Unit, Department of Genetics, Institut Imagine, Paris Descartes University-Sorbonne Paris Cité, Necker Enfants-Malades Hospital, Paris, France.
  • Mahaut C; INSERM U781 Unit, Department of Genetics, Institut Imagine, Paris Descartes University-Sorbonne Paris Cité, Necker Enfants-Malades Hospital, Paris, France.
  • Afenjar A; Neuropediatry Department, Centre de Référence Maladies Rares 'anomalies du développement et syndromes malformatifs - Île de France', Armand-Trousseau CHU, Paris, France.
  • Brooks AS; Department of Clinical Genetics, Ersamus MC, Rotterdam, The Netherlands.
  • Campeau PM; Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Destree A; Department of Human Genetics, Institute of Pathology and Genetics, Gosselies, Belgium.
  • Di Rocco M; Unit of Rare Diseases, Department of Pediatrics, Gaslini Institute, Genoa, Italy.
  • Donnai D; Manchester Academic Health Science Centre, Genetic Medicine-University of Manchester, St Mary's Hospital, Manchester, UK.
  • Hennekam R; Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Heron D; Genetics and Cytogenetics Department, GRC-upmc,Pitié-Salpétrière CHU, Paris, France.
  • Jacquemont S; Department of Genetics, CHUV, Vaud, Switzerland.
  • Kannu P; Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Lin AE; Medical Genetics, Massachussets General Hospital for Children, Boston, MA, USA.
  • Manouvrier-Hanu S; Department of Clinical Genetics, University Hospital, Lille, France.
  • Mansour S; Clinical Genetics, St George's Healthcare NHS Trust, London, UK.
  • Marlin S; Genetic and Medical Embryology Unit, Centre de Référence des Surdités Génétiques, Armand-Trousseau CHU, Paris, France.
  • McGowan R; West of Scotland Regional Genetics Service, Glasgow, UK.
  • Murphy H; Manchester Academic Health Science Centre, Genetic Medicine-University of Manchester, St Mary's Hospital, Manchester, UK.
  • Raas-Rothschild A; Institute of Human Genetics, Meir Medical Center, Kfar Saba, Israel.
  • Rio M; INSERM U781 Unit, Department of Genetics, Institut Imagine, Paris Descartes University-Sorbonne Paris Cité, Necker Enfants-Malades Hospital, Paris, France.
  • Simon M; Department of Clinical Genetics, Ersamus MC, Rotterdam, The Netherlands.
  • Stolte-Dijkstra I; Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Stone JR; Department of Pathology, Massachussets General Hospital, Boston, MA, USA.
  • Sznajer Y; Center for Human Genetics, Cliniques Universitaires St-Luc, Brussels, Belgium.
  • Tolmie J; West of Scotland Regional Genetics Service, Glasgow, UK.
  • Touraine R; Department of Clinical Genetics, Saint-Etienne CHU, Saint-Etienne, France.
  • van den Ende J; Department of Medical Genetics, University and University Hospital Antwerp, Edegem, Belgium.
  • Van der Aa N; Department of Medical Genetics, University and University Hospital Antwerp, Edegem, Belgium.
  • van Essen T; Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Verloes A; Department of Genetics, INSERM U676, AP-HP, Robert Debré Hospital, Paris, France.
  • Munnich A; INSERM U781 Unit, Department of Genetics, Institut Imagine, Paris Descartes University-Sorbonne Paris Cité, Necker Enfants-Malades Hospital, Paris, France.
  • Cormier-Daire V; INSERM U781 Unit, Department of Genetics, Institut Imagine, Paris Descartes University-Sorbonne Paris Cité, Necker Enfants-Malades Hospital, Paris, France.
Eur J Hum Genet ; 22(11): 1272-7, 2014 Nov.
Article em En | MEDLINE | ID: mdl-24424121
ABSTRACT
Myhre syndrome is characterized by short stature, brachydactyly, facial features, pseudomuscular hypertrophy, joint limitation and hearing loss. We identified SMAD4 mutations as the cause of Myhre syndrome. SMAD4 mutations have also been identified in laryngotracheal stenosis, arthropathy, prognathism and short stature syndrome (LAPS). This study aimed to review the features of Myhre and LAPS patients to define the clinical spectrum of SMAD4 mutations. We included 17 females and 15 males ranging in age from 8 to 48 years. Thirty were diagnosed with Myhre syndrome and two with LAPS. SMAD4 coding sequence was analyzed by Sanger sequencing. Clinical and radiological features were collected from a questionnaire completed by the referring physicians. All patients displayed a typical facial gestalt, thickened skin, joint limitation and muscular pseudohypertrophy. Growth retardation was common (68.7%) and was variable in severity (from -5.5 to -2 SD), as was mild-to-moderate intellectual deficiency (87.5%) with additional behavioral problems in 56.2% of the patients. Significant health concerns like obesity, arterial hypertension, bronchopulmonary insufficiency, laryngotracheal stenosis, pericarditis and early death occurred in four. Twenty-nine patients had a de novo heterozygous SMAD4 mutation, including both patients with LAPS. In 27 cases mutation affected Ile500 and in two cases Arg496. The three patients without SMAD4 mutations had typical findings of Myhre syndrome. Myhre-LAPS syndrome is a clinically homogenous condition with life threatening complications in the course of the disease. Our identification of SMAD4 mutations in 29/32 cases confirms that SMAD4 is the major gene responsible for Myhre syndrome.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Deformidades Congênitas da Mão / Criptorquidismo / Proteína Smad4 / Transtornos do Crescimento / Hipertrofia / Artropatias / Deficiência Intelectual Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Deformidades Congênitas da Mão / Criptorquidismo / Proteína Smad4 / Transtornos do Crescimento / Hipertrofia / Artropatias / Deficiência Intelectual Idioma: En Ano de publicação: 2014 Tipo de documento: Article